李玉龍
發(fā)表于3分鐘前
回復
新城毅彥 : People tour Jiuzhou ancient town in Qiandongnan Miao and Dong Autonomous Prefecture, southwest China's Guizhou Province, Jan. 26, 2023. (Photo by Wang Chao/Xinhua)People tour Lijiang ancient town in southwest China's Yunnan Province, Jan. 24, 2023. (Photo by Zhao Qingzu/Xinhua)People enjoy "iron flowers," a folk art performance of throwing molten iron to create fireworks, in Liushuigou Village of Huaying City, southwest China's Sichuan Province, Jan. 25, 2023. (Photo by You Qing/Xinhua)People have fun at Harbin Ice and Snow World in Harbin, northeast China's Heilongjiang Province, Jan. 24, 2023. (Xinhua/Zhang Tao)Photo taken on Jan. 23, 2023 shows people at a cinema in Xi'an, northwest China's Shaanxi Province. (Xinhua/Li Yibo)Tourists take a selfie at a traditional culture street in north China's Tianjin, Jan. 26, 2023. (Xinhua/Zhao Zishuo)Tourists visit an exhibition at the Qilou ancient street during the Spring Festival holiday in Haikou, south China's Hainan Province, Jan. 27, 2023. (Xinhua/Guo Cheng)Tourists enjoy performance at the Qilou ancient street during the Spring Festival holiday in Haikou, south China's Hainan Province, Jan. 27, 2023. (Xinhua/Guo Cheng)Tourists visit the Qilou ancient street during the Spring Festival holiday in Haikou, south China's Hainan Province, Jan. 27, 2023. (Xinhua/Guo Cheng)Tourists visit the Dongpo Academy during the Spring Festival holiday in Danzhou, south China's Hainan Province, Jan. 22, 2023. (Xinhua/Guo Cheng)Tourists visit the Dongpo Academy during the Spring Festival holiday in Danzhou, south China's Hainan Province, Jan. 22, 2023. (Xinhua/Guo Cheng)Tourists visit the Qilou ancient street during the Spring Festival holiday in Haikou, south China's Hainan Province, Jan. 27, 2023. (Xinhua/Guo Cheng)Visitors watch seagulls at the Zhanqiao bridge scenic spot in Qingdao, east China's Shandong Province, Jan. 26, 2023. Watching seagulls during Spring Festival is a tradition in Qingdao. Nowadays, with the improvement of ecological environment, the species of seagulls in Qingdao has increased to over 20 and the amount has surpassed 100, 000. (Xinhua/Li Ziheng)Visitors watch seagulls at the Zhanqiao bridge scenic spot in Qingdao, east China's Shandong Province, Jan. 26, 2023. Watching seagulls during Spring Festival is a tradition in Qingdao. Nowadays, with the improvement of ecological environment, the species of seagulls in Qingdao has increased to over 20 and the amount has surpassed 100, 000. (Xinhua/Li Ziheng)Visitors interact with seagulls at the Zhanqiao bridge scenic spot in Qingdao, east China's Shandong Province, Jan. 26, 2023. Watching seagulls during Spring Festival is a tradition in Qingdao. Nowadays, with the improvement of ecological environment, the species of seagulls in Qingdao has increased to over 20 and the amount has surpassed 100, 000. (Xinhua/Li Ziheng)Visitors watch seagulls in Qingdao, east China's Shandong Province, Jan. 26, 2023. Watching seagulls during Spring Festival is a tradition in Qingdao. Nowadays, with the improvement of ecological environment, the species of seagulls in Qingdao has increased to over 20 and the amount has surpassed 100, 000. (Xinhua/Li Ziheng)Visitors interact with seagulls at the Zhanqiao bridge scenic spot in Qingdao, east China's Shandong Province, Jan. 26, 2023. Watching seagulls during Spring Festival is a tradition in Qingdao. Nowadays, with the improvement of ecological environment, the species of seagulls in Qingdao has increased to over 20 and the amount has surpassed 100, 000. (Xinhua/Li Ziheng) 編輯：王?
王巍
發(fā)表于1小時前
回復
葉永健 : Pharmacists check prescription information at a fever clinic in Minhang district of Shanghai on Jan 8. The small molecule drugs to treat COVID-19 had been put into use in community health centers in Shanghai to better play their roles in "early detection, early intervention and early diversion". WANG XIANG/XINHUADomestically?developed?COVID-19?drug?therapies?lower?risk?of?hospitalizationChina will create broad-spectrum treatments to tackle mutated strains of the COVID-19 virus and develop drugs with novel mechanisms to fight the pathogen, according to a document provided to China Daily.As of Jan 19, a total of 10 domestically made COVID-19 drugs had either been granted official or conditional market approval or were authorized to treat symptoms of the pathogen, the document stated.The document was issued by the specialized team for COVID-19 medicine research and development under the Joint Prevention and Control Mechanism of the State Council, China's Cabinet.China also had 23 drugs on the key COVID-19 medicine list that were in active development or undergoing real-world evidence studies after receiving market approval, it said."The team will continue to facilitate the development of safe and effective treatments that can cover the whole course of the disease and are suitable for all populations," it added.Since the COVID-19 pandemic began, China's novel coronavirus drug development process has followed three broad technical paths- stopping the virus from entering cells, inhibiting viral replication in the body and regulating the body's immune system.In December 2021, China granted official market approval to its first homegrown neutralizing monoclonal neutralizing antibody cocktails - BRII-196 and BRII-198. It is a combination therapy administered through intravenous infusion that can lower the risk of hospitalization and death by nearly 80 percent, according to its phase-three clinical trial results.Meanwhile, Chinese scientists have been developing small-molecule oral treatments for COVID-19.A breakthrough came in July when China granted conditional authorization for the oral antiviral Azvudine to treat COVID-19. The drug was originally used to treat HIV.This year, China will accelerate the development of small-molecule oral drugs. In mid-January, the National Medical Products Administration received applications for market approval for new antivirals SIM0417 and VV116. Another antiviral called RAY1216 had recently finished recruiting for its late-stage clinical trials.Besides finding treatments for COVID-19, Chinese scientists are researching new drugs to prevent infections or regulate the body's immune system, with a handful of candidates currently in phase two or three clinical trials. Some notable examples include the targeted inhibitor drug TDI01 and HY3000 peptide nasal spray.zhangzhihao@chinadaily.com.cn 編輯：王?
鄭世龍
